Table 3.
miRNAs associated with hypertension based on species.
| Species | miRNA | SNPs/Target Gene | Subject/Model | Ref. |
|---|---|---|---|---|
| Human | miR-155 | AGTR1: rs5186 (A1166C) | qPCR on blood mononuclear cells from 64 HT (AA: 25; AC: 20; CC: 19); HUVEC cells | [39,55] |
| - | Reporter silencing assay on HEK293T | [40] | ||
| Human | miR-638, -181a, -663, let-7c | - | Microarray. Validated by qPCR. Functional studies with HEK293 cells. qPCR HT vs. NT | [49,64,65] |
| Human | miR-21, -126, -196a, -451 | - | ||
| Human | miR-145,133 | TGF-β | qPCR HT vs. NT | [64,65] |
| Human | miR-122 | SLC7A1: ss52051869 | Genotyping, sequencing, in vitro on HT | [51] |
| Human | miR-505 | FGF18 | qPCR HT vs. NT from plasma, luciferase reporter assay | [52,53] |
| Human | miR-UL112,296-5p,let-7e | Microarray and validated by qPCR on HT vs. NT | [54] | |
| Human | let-7 | - | qPCR on let-7 in HT vs. NT with normal/increased CMIT | [72] |
| Human | miR-155 | eNOS | qPCR and in vitro assay on HUVEC | [55] |
| Human | miR-143 | - | qPCR HT vs. NT | [64] |
| Human | miR-9,126 | VCAM-1, ICAM-1 | qPCR HT vs. NT | [66] |
| Human | miR-126 | VCAM | Microarray, northern blot and fucntional assay on HUVEC | [67] |
| Human | miR-223 | ICAM-1 | Whole genome and miRNA microarray on HDL treated HCAEC, qPCR, luciferase reporter assay | [68] |
| Human | miR-361-5p, miR-362-5p | - | qPCR on SSH vs. SRH | [48] |
| Human | miR-21 | - | 1.HT patients and post antihypertensive treatment. 2 AngII-induced H295R cells | [63] |
| AngII-induced H295R cells and luciferase reporter assay | [46] | |||
| Human | miR-29a/b/c | - | untreated essential hypertension vs. healthy individuals | [70] |
| Human | miR-510 | - | qPCR on HT vs. NT | [71] |
| Human | miR-92a | - | qPCR on miR-92a in HT vs. NT with normal/increased CMIT | [73] |
| Human | miR-4516 | qPCR from exosomes of urine of HT ISS/SS/SR | [47] | |
| Human | miR-221/222 | eNOS, STAT5a, Ets1, Ets2, p21Cip1, p27Kip1 | Mcroarray, Northern blotting on Dicer silenced HUVEC and and EA.hy.926 cells | [56,58] |
| Human, rats, mice | miR-132, 212 | - | Microarray. Validated by qPCR. Humans treated: AngII blocker, β-blocker; rats treated with endothelin, mice treated with AngII | [45] |
| Human, rats, mice | miR-483-3p | AT2R, AGT, ACE1, ACE2 | miRNA array, luciferase reporter assay on HASMC, RASMC, HL-1 cells | [42] |
| Human, mice | miR-146a/b | HuR | qPCR and intro assay on HUVEC and mice tissues induced by inflammatory cytokines | [59] |
| Rats | miR-34b | Cdk6 | qPCR on SHR vs. Wky | [69] |
| Rats | miR-22 | Chga | Luciferase reporter assay, miR-22 antagomir | [91] |
| Mice | miR-143/145 | ACE | Shear stress on EC of Ampkα2−/− mice, qPCR. MiRagen Therapeutics: MGN-2677 | [31,43] |
| Mouse | miR-181a | - | qPCR on BHP/2J mouse circadian HT | [50] |
| Mouse/Zebrafish | miR-126 | VCAM1, SPRED-1, PIK3 regulatory subunit-2 | miR-126−/− mice, mouse ES cells, antisense to miR-126 | [60,61] |